Notícias e Atividades da Transcenta
Presença
Sede: China
Transcenta é uma empresa listada sob o símbolo 6628 (CN).
Executivos
Veja o organograma con seus 14 executivos principais
Biografias mais buscadas da Transcenta
- Xueming Qian, Chief Executive Officer and Chairman of the Board
- Helen Chen, Independent Non-Executive Director
- Jiasong Tang, Independent Non-Executive Director
Recentes movimentos de executivos em Transcenta
- Christopher Hwang, ingressou na Companhia como Head of Global Partnerships, HiCB Platform (Notícia publicada em 31 de março de 2026).
Criar um alerta
para seguir os movimentos de executivos da Transcenta.
Biotecnologia
Transcenta possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).
Popular M&A news in Biotecnologia
- IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
- NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (publicado em 1 de junho de 2026)..
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Transcenta
- Transcenta Reports Receipt of HiCB Out-licensing Milestone Payment and Steady CDMO Business Growth-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta’s Partner Inhibrx Reports Positive Updated CRC Data for Ozekibart and Announces U.S. BLA Submission for Chondrosarcoma-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeuti
- Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-line G/GEJ Cancer at ESMO Asia-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta’s Partner Inhibrx Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma, with a BLA Submission Planned for 2026-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Announces the Appointment of Tyler Marciniak as Senior Vice President of Capital Markets, Investor Relations and Corporate Communications-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Strengthens Promise for Osemitamab (TST001) for G/GEJ Cancer with OS Data from First-Line Triple Combo Trial Unveiled at 2025 ASCO Annual Meeting-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Debuts Promising Anti-Tumor Activity of Novel FGFR2b Targeting ADC with Site-Specific Conjugated Topo I Inhibitor Payload in Preclinical Tumor Models at AACR 2025-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- View more press releases Close
Redes sociais sobre Transcenta
- Transcenta na Wikipedia, Google News e Yahoo Finance
- Transcenta na LinkedIn, X (Twitter) e YouTube
